Redhill Biopharm

RDHL NASDAQ
6.87
+0.18
+2.61%
Closed 16:00 08/16 EDT
Open
6.74
Prev Close
6.70
High
6.93
Low
6.74
Volume
22.36K
Avg Vol (3M)
72.86K
52 Week High
9.57
52 Week Low
5.13
% Turnover
1.05%
Market Cap
14.66M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Redhill Biopharm RDHL stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn's disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).
MORE >

Recently

Name
Price
%Change